| Literature DB >> 32834500 |
Bakht Ramin Shah1, Bin Li2, Haleama Al Sabbah3, Wei Xu4, Jan Mráz1.
Abstract
BACKGROUND: Dietary fibers (DFs) are known as potential formulations in human health due to their beneficial effects in control of life-threatening chronic diseases including cardiovascular disease (CVD), diabetes mellitus, obesity and cancer. In recent decades scientists around the globe have shown tremendous interest to evaluate the interplay between DFs and gastrointestinal (GIT) microbiota. Evidences from various epidemiological and clinical trials have revealed that DFs modulate formation and metabolic activities of the microbial communities residing in the human GIT which in turn play significant roles in maintaining health and well-being. Furthermore, interestingly, a rapidly growing literature indicates success of DFs being prebiotics in immunomodulation, namely the stimulation of innate, cellular and humoral immune response, which could also be linked with their significant roles in modulation of the probiotics (live beneficial microorganisms). SCOPE AND APPROACH: The main focus of the current review is to expressively highlight the importance of DFs being prebiotics in human health in association with their influence on gut microbiota. Now in order to significantly achieve the promising health benefits from these prebiotics, it is aimed to develop novel formulations to enhance and scale up their efficacy. Therefore, finally, herein unlike previously published articles, we highlighted different kinds of prebiotic and probiotic formulations which are being regarded as hot research topics among the scientific community now a days.Entities:
Keywords: CS, chitosan; Dietary fiber; Encapsulation; FOS, Fructooligosaccharide; Formulations; GIT, Gastro intestinal tract; GO, gum odina; Gut micro-biota; Human health; In, Inulin; MD, maltodextrin; OL, oligofructose; OSA, octenyl-succinic anhydride; PS, potato starch; PSY, plantago psyllium; Prebiotics
Year: 2020 PMID: 32834500 PMCID: PMC7309926 DOI: 10.1016/j.tifs.2020.06.010
Source DB: PubMed Journal: Trends Food Sci Technol ISSN: 0924-2244 Impact factor: 12.563
Fig. 1Key factors influencing the composition as well as metabolic activities of gut microbiota.
Fig. 2Roles and potential health benefits of prebiotics & probiotics.
Fig. 3Interplay between dietary fiber and colonic microbiome.
Summary of clinical trials based on applications of prebiotics and probiotics aimed for the treatments of different diseases.
| S. No | Study design | Name of disease | No. of patients | Age group (in years) | Duration of the study | Name of pre & prebiotic used | Control group | Main outcome of the study | References |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Randomized Control Trial (RCT) | Irritable bowel syndrome (IBS) | 39 | 19–75 | 4 weeks | Placebo | Significantly enhanced the fecal contents of most probiotic strains. | ||
| 2 | Double Blind Clinical Trial | Inflammatory bowel disease (IBD) | 105 | 36–38 | 8 weeks | Placebo | Significantly increased the numbers of | ||
| 3 | Randomized, Double-Blind, Placebo-Controlled Trial | Infantile colic | 24 | <1 (3 weeks-6 months) | 21 days | Placebo | Significantly improved colic symptoms | ||
| 4 | RCT | Necrotizing enterocolitis (NEC) | 400 | <1 (<32 weeks) | 8 weeks | Placebo | Probiotic ( | ||
| 5 | RCT | Nonalcoholic fatty liver disease (NAFLD) | 42 | 18–65 | 8 weeks | Placebo | Significantly reduced insulin, insulin resistance, TNF-a, and IL-6 decreased | ||
| 6 | RCT | Rheumatoid arthritis (RA) | 46 | 20–80 | 8 weeks | Placebo | No significant effect on oxidative status was observed between the treated and placebo groups | ||
| 7 | Randomized, Double-Blind, | RA | 30 | 25–70 | 8 weeks | Placebo | Significantly improved Disease Activity Score of 28 Joints (DAS-28). | ||
| 8 | Randomized, Double-Blind, | Alzheimer's Disease (AD) | 60 | 60–95 | 12 weeks | Placebo | Significantly improved Mini-mental state examination (MMSE)score in the treated group. | ||
| 9 | Randomized, Double-Blind, | Parkinson disease (PD) | 120 | 71.8 ± 7.7 | 4 weeks | Placebo | Significantly improved constipation in PD patients. | ||
| 10 | Randomized, Double-Blind, Placebo-Controlled Trial | Overweight diabetic patients with coronary heart disease (CHD). | 30 | 40–85 | 12 weeks | Placebo | Significantly decreased plasma glucose, serum insulin concentrations. | ||
| 11 | Double-Blind, Placebo-Controlled Trial | IBS | 54 | 18–70 | 8 weeks | Placebo | No significant difference was observed between the treated and placebo groups | ||
| 12 | Randomized Triple-Blind | NAFLD | 64 | 10–18 | 12 weeks | Placebo | Significantly decreased levels of alanine aminotransferase, mean aspartate aminotransferase, mean cholesterol, low-density lipoprotein-C, and triglycerides as well as waist circumference in the intervention group. | ||
| 13 | Double-Blind, Placebo-Controlled Trial | Overweight or obesity | 22 | 7–12 | 12 weeks | Oligofructose-enriched inulin | Placebo | Significantly decreased body weight z-score, percent body fat, and percent trunk fat and levels of interleukin 6 and serum triglycerides in the treated group. | |
| 14 | Randomized, Double-Blind, Placebo-Controlled Trial | IBS | 22 | 30–50 | 10 weeks | Placebo | |||
| 15 | Randomized Double-Blind Placebo-Controlled Clinical Trial | Diabetes | 60 | 54.0 ± 16.0 | 12 weeks | Placebo | Significantly decreased fasting plasma glucose, homeostasis model of assessment-estimated insulin resistance, homeostasis model of assessment-estimated beta-cell function and HbA1c, and improved quantitative insulin sensitivity check index. | ||
| 16 | Randomized, Double-Blind Trial | Overweight or obesity | 21 | 20–59 | 8 weeks | Placebo | Significantly reduced the waist circumference, waist-height ratio, conicity index, and plasma polyunsaturated fatty acids and increased the activity of glutathione peroxidase. | ||
| 17 | Double Blind Randomized Clinical Trial | NAFLD | 75 | 20–60 | 12 weeks | Placebo | Supplementation with probiotics and/or prebiotics improved amino transferase enzymes, and supplementation with probiotics or pro- and prebiotics recovered the grade of fatty liver in NAFLD patients. | ||
| 18 | Randomized, Double-Blind, Placebo-Controlled Trial | Overweight and obese type-2 diabetes | 60 | 30–55 | 45 days | Sodium butyrate and inulin | Placebo | Significantly improved | |
| 19 | Randomized Controlled Clinical Trial | Diabetic kidney disease (DKD) | 48 | 32–68 | 8 weeks | Placebo | Improved oxidative stress factors among DKD patients | ||
| 20 | Double Blind Randomized Clinical Trial | NAFLD | 84 | 20–60 | 12 weeks | Placebo | Probiotic and prebiotic supplementation improved serum lipid profile and insulin resistance markers in NAFLD patients. | ||
| 21 | Placebo-Controlled, | Major depressive disorder | 81 | 18–50 | 8 weeks | Placebo | Improved Beck Depression Inventory (BDI) score in the treatment group | ||
| 22 | Single-Blind, Parallel, Randomized, Placebo-Controlled Trial | Overweight or obesity | 41 | 30–65 | 12 weeks | Placebo | The formulated synbiotic pasta showed synbiotic exhibited beneficial effects on plasma resistin, plasma LDL/HDL cholesterol ratio, and plasma hs-CRP | ||
| 23 | Double-Blind, Placebo-Controlled, Randomized Clinical Trial | Overweight or obesity | 50 | 20–60 | 12 weeks | Placebo | Significantly improved obesity-related markers in obese people |
Summary of recent advancements in prebiotics and probiotics formulations
| S. No | Name of prebiotic or probiotic used | Formulations | Potentials of the formulations | References |
|---|---|---|---|---|
| 1 | alginate-chitosan capsules | To enhance survival of the probiotic bacteria and keeping intact the prebiotic during exposure to the adverse conditions of the GIT | ||
| 2 | Inulin, FOS, polydextrose, and resistant starch | Meat emulsion | To reduce sodium chloride and pork-back-fat contents of the emulsified meat product (bologna) | |
| 3 | Probiotic | Microcapsules | To improve stability of the microcapsules and protect the encapsulated probiotic | |
| 4 | Inulin | Emulsion filled gels | To reduce fat content in the foods | |
| 5 | Emulsion | To enhance viability of the encapsulated probiotic bacteria | ||
| 6 | Inulin | Emulsion | To enhance the retention and antioxidant efficacy of geranylgeraniol (bioactive compound) | |
| 7 | Inulin | Nanocomplexes | Protection and delivery of encapsulated resveratrol and to enhance the prebiotic efficacy of the complexes | |
| 8 | Inulin | Microcapsules | To enhance protection and retention of the encapsulated thymol | |
| 9 | Emulsion | To enhance viability of the encapsulated probiotic bacteria | ||
| 10 | Potato starch (PS), Plantago psyllium (PSY) and Inulin (IN)) as prebiotics and | Microcapsules | To protect the encapsulated bacteria and enhance their viability | |
| 11 | Lactic acid bacteria as probitioc and cactus pear peel or apple marc flours as prebiotics | Microcapsules | To protect the encapsulated bacteria and enhance their viability | |
| 12 | Inulin (IN), and oligofructose (OL) | Emulsion | To enhance storage, release and antioxidant properties of the encapsulated lime essential oil | |
| 13 | bionanocomposite | To enhance protection of the encapsulated bacteria | ||
| 14 | Emulsion | To enhance viability of the encapsulated probiotic bacteria | ||
| 15 | Gum odina (GO) | Emulsion | To increase bioavailability and patient compliances of the encapsulated anti-retroviral drug lamivudine | |
| 16 | Inulin | Emulsion | To produce reduced fat mayonnaises | |
| 17 | Strawberry juices | To enhance quality parameters (microbiological, antioxidant capacity indicators, and sensory) of the juices and enhance safety and protection of the encapsulants | ||
| 18 | Inulin | Soursop flavored whey beverage | To scale up the physical stability of the system | |
| 19 | Inulin | Whey beverage | To scale up kinetic stability of the system | |
| 20 | Inulin | Emulsion filled gel | To enhance stability and consistency of the synthesized system | |
| 21 | Emulsion | To obtaining a low-saturated fat ice cream functionalized with probiotic bacteria | ||
| 22 | Inulin | Emulsion-filled gel | To produce fermented sausages with reduced fat and improved stability as well as fatty acid composition, | |
| 23 | Inulin | Emulsion | To enhance the stability and thickening of the synthesized system | |
| 24 | Inulin | Emulsion | To enhance the stability and protein digestibility of the formulated enteral formulas | |
| 25 | Alginate microparticles | To enhance viability of the encapsulated probiotic bacteria | ||
| 26 | Nanoemulsion | To enhance viability and protection of the encapsulated probiotic bacteria | ||
| 27 | Emulsion | To enhance growth and survival of the encapsulated proboiotic bacteria | ||
| 28 | Inulin | Liposome and emulsion gels | To enhance oxidative stability of the synthesized system | |
| 29 | octenyl-succinic anhydride (OSA) starch, Inulin (IN), maltodextrin (MD), chitosan (CS) | Nanocapsules | To improve the physicochemical stability and solubility of the encapsulated algal oil | |
| 30 | Emulsion | To enhance protection and viability of the encapsulated probiotic bacteria | ||
| 31 | Lactic acid bacteria | Alginate–pectin gels microcapsules | To enhance protection and viability of the encapsulated bacteria and thereby enhance nutritional value of the cooked sausages | ( |
| 32 | Inulin and konjac glucomannan | Emulsion | To scale up the stability and rheological properties of the emulsions | |
| 33 | pectin microparticles | To enhance protection and viability of the encapsulated bacteria |